{
  "emaEpar": [
    {
      "activeSubstance": "pemetrexed disodium hemipentahydrate",
      "conditionIndication": "Malignant pleural mesotheliomaPemetrexed Accord in combination with cisplatin is indicated for the treatment of chemotherapy na\u00efve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancerPemetrexed Accord in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.Pemetrexed Accord is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.Pemetrexed Accord is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.",
      "inn": "pemetrexed",
      "marketingAuthorisationDate": "2016-01-18 01:00:00",
      "marketingAuthorisationHolder": "Accord Healthcare S.L.U.",
      "medicineName": "Pemetrexed Accord",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-accord"
    },
    {
      "activeSubstance": "pemetrexed",
      "conditionIndication": "Malignant pleural mesotheliomaPemetrexed Fresenius Kabi in combination with cisplatin is indicated for the treatment of chemotherapy na\u00efve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancerPemetrexed Fresenius Kabi in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.Pemetrexed Fresenius Kabi is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. Pemetrexed Fresenius Kabi is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.",
      "inn": "pemetrexed",
      "marketingAuthorisationDate": "2016-07-22 00:00:00",
      "marketingAuthorisationHolder": "Fresenius Kabi Deutschland GmbH",
      "medicineName": "Pemetrexed Fresenius Kabi",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-fresenius-kabi"
    },
    {
      "activeSubstance": "pemetrexed disodium",
      "conditionIndication": "Malignant pleural mesotheliomaPemetrexed Krka in combination with cisplatin is indicated for the treatment of chemotherapy na\u00efve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancerPemetrexed Krka in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.Pemetrexed Krka is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.Pemetrexed Krka is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.",
      "inn": "pemetrexed",
      "marketingAuthorisationDate": "2018-05-22 00:00:00",
      "marketingAuthorisationHolder": "KRKA d.d.",
      "medicineName": "Pemetrexed Krka",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-krka"
    },
    {
      "activeSubstance": "pemetrexed",
      "conditionIndication": "Malignant pleural mesotheliomaAlimta in combination with cisplatin is indicated for the treatment of chemotherapy-na\u00efve patients with unresectable malignant pleural mesothelioma.Non-small-cell lung cancerAlimta in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology.Alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.Alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology.",
      "inn": "pemetrexed",
      "marketingAuthorisationDate": "2004-09-20 00:00:00",
      "marketingAuthorisationHolder": "Eli Lilly Nederland B.V.",
      "medicineName": "Alimta",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/alimta"
    },
    {
      "activeSubstance": "pemetrexed",
      "conditionIndication": "Malignant pleural mesotheliomaPemetrexed Hospira in combination with cisplatin is indicated for the treatment of chemotherapy na\u00efve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancerPemetrexed Hospira in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.Pemetrexed Hospira is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.Pemetrexed Hospira is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.",
      "inn": "pemetrexed",
      "marketingAuthorisationDate": "2015-11-19 01:00:00",
      "marketingAuthorisationHolder": "Pfizer Europe MA EEIG",
      "medicineName": "Pemetrexed Hospira",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-hospira"
    },
    {
      "activeSubstance": "pemetrexed",
      "conditionIndication": "Malignant pleural mesothelioma Pemetrexed medac in combination with cisplatin is indicated for the treatment of chemotherapy na\u00efve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancer Pemetrexed medac in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.Pemetrexed medac is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.Pemetrexed medac is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.",
      "inn": "pemetrexed",
      "marketingAuthorisationDate": "2015-11-26 01:00:00",
      "marketingAuthorisationHolder": "medac Gesellschaft f\u00fcr klinische Spezialpr\u00e4parate mbH",
      "medicineName": "Pemetrexed medac",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-medac"
    },
    {
      "activeSubstance": "pemetrexed diacid monohydrate",
      "conditionIndication": "Malignant pleural mesothelioma, , Pemetrexed in combination with cisplatin is indicated for the treatment of chemotherapy na\u00efve patients with unresectable malignant pleural mesothelioma., , Non-small cell lung cancer, , Pemetrexed in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology., , Pemetrexed is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy., , Pemetrexed is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology., ",
      "inn": "pemetrexed",
      "marketingAuthorisationDate": "2016-01-18 01:00:00",
      "marketingAuthorisationHolder": "Actavis Group PTC ehf",
      "medicineName": "Armisarte (previously Pemetrexed Actavis)",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/armisarte"
    },
    {
      "activeSubstance": "pemetrexed disodium hemipentahydrate",
      "conditionIndication": "Malignant pleural mesothelioma, , Pemetrexed Sandoz in combination with cisplatin is indicated for the treatment of chemotherapy naive patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancer, , Pemetrexed Sandoz in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology., Pemetrexed Sandoz is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy., Pemetrexed Sandoz is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology., ",
      "inn": "pemetrexed",
      "marketingAuthorisationDate": "2015-09-18 00:00:00",
      "marketingAuthorisationHolder": "Sandoz GmbH",
      "medicineName": "Pemetrexed Sandoz",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-sandoz"
    },
    {
      "activeSubstance": "pemetrexed disodium hemipentahydrate",
      "conditionIndication": "Malignant pleural mesotheliomaCiambra in combination with cisplatin is indicated for the treatment of chemotherapy na\u00efve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancerCiambra in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.Ciambra is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.Ciambra is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.",
      "inn": "pemetrexed",
      "marketingAuthorisationDate": "2015-12-02 01:00:00",
      "marketingAuthorisationHolder": "Menarini International Operations Luxembourg S.A.",
      "medicineName": "Ciambra",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/ciambra"
    },
    {
      "activeSubstance": "pemetrexed",
      "conditionIndication": "Malignant pleural mesotheliomaPemetrexed Lilly in combination with cisplatin is indicated for the treatment of chemotherapy na\u00efve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancerPemetrexed Lilly in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.Pemetrexed Lilly is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.Pemetrexed Lilly is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non small cell lung cancer other than predominantly squamous cell histology.",
      "inn": "pemetrexed",
      "marketingAuthorisationDate": "2015-09-14 00:00:00",
      "marketingAuthorisationHolder": "Eli Lilly Netherlands",
      "medicineName": "Pemetrexed Lilly",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-lilly"
    },
    {
      "activeSubstance": "pemetrexed ditromethamine",
      "conditionIndication": "Malignant pleural mesothelioma, , Pemetrexed Hospira UK Limited in combination with cisplatin is indicated for the treatment of chemotherapy na\u00efve patients with unresectable malignant pleural mesothelioma., , Non-small cell lung cancer, , Pemetrexed Hospira UK Limited in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see SmPC section 5.1)., , Pemetrexed Hospira UK Limited is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see SmPC section 5.1)., , Pemetrexed Hospira UK Limited is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see SmPC section 5.1)., ",
      "inn": "pemetrexed",
      "marketingAuthorisationDate": "2017-04-24 00:00:00",
      "marketingAuthorisationHolder": "Pfizer Europe MA EEIG",
      "medicineName": "Pemetrexed Pfizer (previously known as Pemetrexed Hospira UK Limited)",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-pfizer-previously-known-pemetrexed-hospira-uk-limited"
    }
  ],
  "fdaDrugLabel": [],
  "id": "Pemetrexed",
  "nciThesaurus": {
    "casRegistry": "137281-23-3",
    "chebiId": "CHEBI:63616",
    "chemicalFormula": "C20H21N5O6",
    "definition": "A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.",
    "fdaUniiCode": "04Q9AIZ7NO",
    "identifier": "C61614",
    "preferredName": "Pemetrexed",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C2021",
      "C511"
    ],
    "synonyms": [
      "L-Glutamic Acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)",
      "MTA",
      "Multitargeted Antifolate",
      "PEMETREXED",
      "Pemetrexed",
      "Pemfexy"
    ]
  }
}